Research Insight
Landmark study confirms complexity and informs the next stages of research
The largest population genome sequencing effort to date is published today in Nature. A series of papers describing resources and application of the data is published at the same time in Nature, Nature Genetics, Bioinformatics and Nature Communications. ...
Research Insight
Amgen and Kite Pharma to develop CAR T cell immunotherapies
US-based Amgen has signed a strategic research collaboration and license agreement with Kite Pharma to develop and commercialise chimeric antigen receptor (CAR) T cell immunotherapies. The immunotherapies will be developed based on Kite's engineered autologous cell...
Research Insight
TxCell and Ferring partner with Trizell to further develop Ovasave to treat IBD
France-based TxCell and Switzerland's Ferring International have partnered with Trizell Holding to further enhance the development of TxCell's Ovasave to treat inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. The collaboration, option, development and...
Research Insight
Novartis, Intellia and Caribou to develop new medicines and drug discovery tools
Swiss drug-maker Novartis has entered collaboration and licensing agreements with Intellia Therapeutics to develop new medicines using CRISPR genome editing technology and Caribou Biosciences for drug discovery tools. CRISPR is an acronym for clustered regularly interspaced...
Research Insight
New technology may detect nucleic acid biomarkers of cancer
A new technique has been developed utilizing nanotechnology to detect disease biomarkers in the form of nucleic acids.The proof-of-concept study came from a team of researchers at Wake Forest Baptist Medical Center The proof-of-concept...
Research Insight
UK Medical Research Council scientists create world’s first synthetic enzymes
Scientists at the UK's Medical Research Council (MRC) have created the world's first enzymes made from artificial genetic material, which are capable of triggering chemical reactions in the laboratory. Synthetic enzymes are made from...
Research Insight
Hilleman signs MoU with Bangladesh firms to develop oral cholera vaccine
Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine. The collaboration was established to fast track...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read